ARRA Funding Update, December 23, 2009
The 2009 American Recovery and Reinvestment Act (ARRA) was a unique effort to jumpstart our economy. In this Director's Message I have updated NINDS's progress on implementing the 2009 American Recovery and Reinvestment Act (ARRA). NINDS grants funded through the ARRA mechanism have already led to job creation and retention. The results of the funded research will serve to advance neuroscience and positively impact the neurological health of the country. I also encourage the scientific community to communicate back to me how ARRA has contributed to jobs and advanced science in your community.
Earlier this year the NIH was allocated $10.4 billion through the ARRA to simulate the U.S. economy by creating jobs and funding high quality research. Of these funds, NINDS was given approximately $400 million. Most of these funds were committed by September 30, 2009 to support a number of outstanding projects, including meritorious grant applications, trans-NIH targeted supplement programs, Challenge grants, "GO" grants, and the NIMH Autism initiative, as well as other initiatives. What follows is a progress report on how we invested most of the funds. Even more detailed information on NIH awards can be found at http://projectreporter.nih.gov. Please continue to check our website where we will post more information as it becomes available.
1. NINDS funded particularly meritorious grant applications that scored above the payline.
2. NINDS participated in the trans-NIH targeted supplement programs.
3. NINDS participated in the trans-NIH Challenge Grant program.
4. NINDS supported new faculty hires.
5. NINDS participated in the trans-NIH Research and Research Infrastructure Grand Opportunities ("GO") Grants Program
6. NINDS participated in the NIMH Autism RFA-MH-09-170 under which
NINDS awarded 8 grants totaling $ 5,617,658.
7. The remaining ARRA funds approximately $17 million are allocated for funding meritorious applications from three additional initiatives: the Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3); the Recovery Act Limited Competition: Small Business Catalyst Awards for Accelerating Innovative Research (R43); and the Recovery Act Limited Competition: Academic Research Enhancement Award (R15).
8. NINDS Signature Project: Genetics and Genomics of Neurological Disorders During the past two decades, the genetic causes of monogenic forms of a number of neurological diseases have been successfully identified, resulting in significant progress in basic understanding of disease mechanisms, molecular diagnoses, pre-clinical and translational research, and promising treatment strategies. To extend this success and define genetic loci for additional monogenic disorders as well as genetic risk factor loci for complex, multifactorial neurological disorders, NINDS designed a signature project, "Genetics and Genomics of Neurological Disorders." This project focuses on identifying genes that cause disease as well as those that confer susceptibility. The project will enable investigators to leverage next-generation sequencing and other emerging technologies that can elucidate genetic variants associated with neurological disorders and attribute functional or disease-causing properties when they exist in combination with other variants or environmental factors.
Last Modified March 1, 2016